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Introduction
In Canada the use of Omalizumab is restricted to
patients with moderate to severe allergic asthma. How-
ever there are some cases reports showing its effective-
ness in other conditions like chronic urticaria, ABPA
and patients with nasal polyps and asthma. Although
there are also reports of using omalizumab in patients
with cystic fibrosis and ABPA, there are not controlled
trials confirming their efficacy.
Case report
A seventeen year old girl diagnosed with Cystic Fibrosis
at the age of 6 and subsequently developed ABPA at the
age of 15 but also had clear evidence of bronchial
asthma confirmed by history and spirometry. She also
had significant environmental allergies.
The diagnosis of ABPA was confirmed based on 5 or
more criteria accepted by international committees and
Cystic Fibrosis by genetic testing. She also had pancrea-
tic insufficiency consistent with Cystic Fibrosis.
Because her condition was gradually deteriorating
requiring despite the use frequent courses of antibiotics,
prednisone and admissions to the hospital, it was
decided to place her on omalizumab in August 2012.
The dose based on her weight and total IgE was 225 mg
every 2 weeks.
Results
She felt better subjectively within two months after she
was placed on omalizumab and after almost 2 years of
treatment she had a significant improvement in all
objective parameters including lab investigations,
decreased need for steroids, antibiotics, admissions to
the hospital and quality of life. She has not had any
adverse reactions.
Summary
It is known that Cystic Fibrosis together with ABPA will
induce a more significant deterioration of the lung func-
tion than either alone and seriously interferes with qual-
ity of life. However, it appears that adding omalizumab
to her current treatment has had an overall significant
benefit that was sustained over 2 years.
The authors are aware that although it is unlikely that
there will be RCT in this unique group of patients, case
reports such as the one presented, might encourage
others to follow the same approach in specific patients.
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